The past decade had larger and more extensive Ebola virus disease (EVD) outbreaks in Africa with no licensed treatments available. In view of the unmet medical need for prophylactic Ebola vaccines, researchers herein examined the safety as well as immunogenicity of a 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy African children.

• Researchers conducted a randomized, placebo-controlled, phase 2 clinical trial; African participants in 2 age cohorts (12 to 17 and 4 to 11 years) were administered the Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination regimen.

• There was no report of vaccine-related serious adverse events, and both adolescents and children show induction of robust immune responses after receiving the active 2-dose regimen.

• Overall data yield support for using the Ad26.ZEBOV, MVA-BN-Filo vaccination regimen in African adolescents and children at risk of Ebola infection.

• Although vaccination according to a 28-day regimen may result in induction of protection against EVD in a shorter time frame, higher EBOV GP binding and neutralizing antibody responses are observed following vaccination according to a 56-day regimen.